Ann: Appendix 4C - quarterly, page-2

"During the Q1 FY perio0d Cann Global through its Research Division, MCRG, invested approximately $1.1M towards the Research on MS being undertaken by the Technion Haifa, that following the earlier success in vitro in the lab, has now seen successful mice trials which are continuing, and trials on patients being monitored by leading Israeli hospitals are also currently underway."

Human trials of the strain that slows down MS have begun. That's fantastic news and has HUGE potential if successful!
Human trials mean is a strong indication the drug is having a positive effect.